{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=7&state=California", "query": { "state": "California", "city": "Fullerton", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 1115, "total_pages": 112, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=8&state=California&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=6&state=California&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T03:43:36.826Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04478266", "title": "Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Amcenestrant-matching placebo", "type": "DRUG" }, { "name": "SAR439859", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Letrozole-matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1068, "start_date": "2020-10-14", "completion_date": "2023-05-26", "has_results": true, "last_update_posted_date": "2025-09-11", "last_synced_at": "2026-10-26T03:43:36.826Z", "location_count": 45, "location_summary": "Daphne, Alabama • Glendale, Arizona • Tucson, Arizona + 40 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04478266" }, { "nct_id": "NCT03228537", "title": "Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Biphasic Mesothelioma", "Epithelioid Mesothelioma", "Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7", "Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7", "Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7", "Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7", "Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Extrapleural Pneumonectomy", "type": "PROCEDURE" }, { "name": "Pemetrexed Disodium", "type": "DRUG" }, { "name": "Pleurectomy", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2018-07-16", "completion_date": "2027-09-18", "has_results": true, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-26T03:43:36.826Z", "location_count": 174, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 121 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Arroyo Grande", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03228537" }, { "nct_id": "NCT05637801", "title": "A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alzheimer Disease", "Alzheimer Disease 1", "Alzheimer Disease 2", "Alzheimer Disease 3", "Alzheimer Disease, Early Onset", "Alzheimer Disease, Late Onset", "Alzheimer Disease 9", "Alzheimer Disease 4", "Alzheimer Disease 7", "Alzheimer Disease 17", "Alzheimer's Dementia Late Onset", "Alzheimer Disease 5", "Alzheimer Disease 6", "Alzheimer Disease 8", "Alzheimer Disease 10", "Alzheimer Disease 11", "Alzheimer Disease 12", "Alzheimer Disease 13", "Alzheimer Disease 14", "Alzheimer Disease 15", "Alzheimer Disease 16", "Alzheimer Disease 18", "Alzheimer Disease 19", "Dementia", "Dementia Alzheimers", "Dementia, Mild", "Dementia of Alzheimer Type", "Dementia Moderate", "Dementia Senile", "Mild Cognitive Impairment", "Mild Dementia", "MCI", "Cognitive Impairment", "Cognitive Decline", "Cognitive Impairment, Mild" ], "interventions": [ { "name": "Spectris™ AD - Active", "type": "DEVICE" }, { "name": "Spectris™ AD - Sham", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Cognito Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 673, "start_date": "2022-12-13", "completion_date": "2026-08-17", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-26T03:43:36.826Z", "location_count": 68, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05637801" }, { "nct_id": "NCT01150045", "title": "Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "celecoxib", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2527, "start_date": "2010-06", "completion_date": "2022-08-11", "has_results": true, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-26T03:43:36.826Z", "location_count": 826, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 536 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01150045" }, { "nct_id": "NCT02921256", "title": "Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Adenocarcinoma", "Stage II Rectal Cancer AJCC v7", "Stage III Rectal Cancer AJCC v7" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 363, "start_date": "2017-01-11", "completion_date": "2023-09-20", "has_results": true, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-10-26T03:43:36.826Z", "location_count": 645, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 449 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02921256" }, { "nct_id": "NCT03525613", "title": "A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Geographic Atrophy" ], "interventions": [ { "name": "APL-2", "type": "DRUG" }, { "name": "Sham Procedure", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Apellis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 637, "start_date": "2018-08-31", "completion_date": "2022-06-28", "has_results": true, "last_update_posted_date": "2023-07-06", "last_synced_at": "2026-10-26T03:43:36.826Z", "location_count": 67, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 56 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03525613" }, { "nct_id": "NCT02079246", "title": "Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Idalopirdine 60 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 1463, "start_date": "2014-04-07", "completion_date": "2017-07-06", "has_results": true, "last_update_posted_date": "2018-08-10", "last_synced_at": "2026-10-26T03:43:36.826Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 56 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Carlsbad", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02079246" }, { "nct_id": "NCT02708680", "title": "Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syndax Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 89, "start_date": "2016-05", "completion_date": "2021-03-31", "has_results": true, "last_update_posted_date": "2024-12-04", "last_synced_at": "2026-10-26T03:43:36.826Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Bakersfield, California • Fullerton, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Redondo Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02708680" }, { "nct_id": "NCT00294723", "title": "To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "liraglutide", "type": "DRUG" }, { "name": "glimepiride", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 746, "start_date": "2006-02", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2017-03-07", "last_synced_at": "2026-10-26T03:43:36.826Z", "location_count": 102, "location_summary": "Concord, California • Escondido, California • Fullerton, California + 83 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "Mission Viejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00294723" }, { "nct_id": "NCT05119569", "title": "A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Fenebrutinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 109, "start_date": "2022-03-01", "completion_date": "2027-06-30", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-26T03:43:36.826Z", "location_count": 2, "location_summary": "Fullerton, California • Las Vegas, Nevada", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05119569" } ] }